glp-3 vs retatrutide New drug significantly slashes both weight and blood sugar levels in Phase III trial GLP-3 Retatrutide (12mg vials) -

DPP-4 inhibitors reduce HbA 1c levels and have a low risk of hypoglycaemia or other adverse events [38], except for a potential risk of hospitalisation for heart failure in the case of saxagliptin [38]

Cell Rep Med 4:101292

The Kidney Disease: Improving Global Outcomes (KDIGO) 2020 clinical practice guidelines recommend GLP-1 receptor agonists as an excellent option for patients with DKD who have not achieved their glycemic target or as an alternative for patients unable to tolerate metformin or an SGLT2 inhibitor [63]

It is important to note that simvastatin effects could have been a confounding factor in this case